Svas Biosana Nine-Month Consolidated Revenue Holds Broadly Steady at EUR 103 Million

PUBT · 2d ago
Svas Biosana Nine-Month Consolidated Revenue Holds Broadly Steady at EUR 103 Million
  • Svas Biosana’s revenue totaled EUR 103 million for the nine months ended September 30, 2026, versus EUR 103.4 million a year earlier.
  • Mark Medical revenue rose 3% to EUR 38 million, helping offset declines elsewhere in the group.
  • Bormia revenue increased 13.6% to EUR 19.2 million, supporting the group’s international business.
  • Farmex revenue fell 10.8% to EUR 23.2 million.
  • Svas revenue declined 5.4%; Medical revenue dropped 2.7%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Svas Biosana S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20240-32-2026_TELEBORSA.pdf), on November 06, 2026, and is solely responsible for the information contained therein.